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The effect of calcium supplements on rectal mucosal proliferation
NC Armitage, PS Rooney, K-A Gifford, PA Clarke and JD Hardcastle
Department ofSurgery, University Hospital, Nottinghamn NG7 2UH, UK.
S ry Seventy-nine patients with colorctal adenomata were randomised to receve calcium carbonate
(3,000mg) or plaebo in a double-blnd randomised trial to assms the short- and long-term effects on rectal
mucosal proiferation mesued by the in vitro aas arrt technique crypt cell producton rate (CCPR).
There was no signifkant difference in mean CCPR between the groups before treatment or after 3 or 12
months. In those paients randonised to calcium, CCPR fel at both 3 months [9.0 (2.8) cc c-' h-, t = 3.15,
d.f = 76, P = 0.0021 and 12 months [9.2 (3.3) cc c' h-' t = 2.7, df. = 74, P = 0.009] compared with pretrat-
ment CCPR [12.2 (5.5) cc c- I h- ]. We have demonstrated that calcium had no effect on mucosal proliferation
compared with placebo. The results on a a fonnation are awaited.
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It is becoming clear that while genetic changes play an
important part in the genesis of colorectal cancer the major
influences are likely to be dietary (Armstrong, 1975; Fearon
and Vogelstein, 1990; Willett et al., 1990). Diet is complex in
most societies, and identifying those constituents which sub-
stantially influence the risk of colorectal cancer is the subject
ofmuch study (Armstrong, 1975; Willett et al., 1990; Thun et
al., 1993). The results of such studies are not as yet clear and
are often conflicting, but it would appear that a diet which is
high in animal fat and low in fibre is associated with a high
risk; conversely, a diet low in fat and high in fibre appears to
be protective (Armstrong, 1975; Willett et al., 1990).
An attempt to modify diet in order to reduce cancer risk is
seen as a possible goal. However, there are two major
difficulties in determining efficacy in diet intervention. The
first is deciding which element of the diet to modify and the
second is the end point required. Clarly the best end point is
the reduction in mortality from colorectal cancer. However,
this would require very large numbers of individuals to be
recruited and studied over decades. Intermediate end points
have therefore been sought, the most obvious of which is the
adenoma, widely held as the benign precursor of most
cancers (Morson, 1974). The incidence of new adenomas or
the change in size of existing adenomas may be useful, since
intervention may cause either a reduction in the number of
new adenomas formed in a 'clean colon' or reduction in
growth or regression of existing adenomas. Fmally, one can
utilise changes in rectal mucosal proliferation. An increase in
mucosal proliferation is thought to be an early step in the
genesis ofcolorectal neoplasia (Fearon and Vogelstein, 1990).
We have previously shown that individuals at increased risk
of colorectal cancer have elevated mucosal proliferation
(Rooney et al., 1993a), and this finding has been confirmed
by others (Terpstra et al., 1987; Anti et al., 1993). Reduction
of rectal mucosal proliferation by an intervention may be
evidence ofan effect on reduction ofrisk ofcolorectal cancer
and perhaps a modification of the progression to cancer.
A number of investigators have studied the effect of cal-
cium on the risk of colorectal cancer. There is some
epidemiological evidence that diets high in calcium may be
protective for colorectal cancer (Garland et al., 1985; Soren-
son et al., 1988). There is no ckar mechanism of action, but
much of its action is thought to be by binding faecal bile
acids and rndeinng them insoluble in the colonic lumen
(Rafter et al., 1986; Van De Meer et al., 1990). Faecal bile
acids have been shown to be tumour promoters in animals
(Reddy et al., 1976) and are thought to play an important
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part in human colorectal carcinogenesis. In animal studies,
calcum can reduce the number of tumours in carcinogen-
treated rodents (Appleton et al., 1987). In addition, calcium
has a antiproliferative action on colonic mucosal prolifera-
tion, as increasing concentrations ofcalcium in organ culture
systems reduces proliferation in human colonic explants
(Appleton et al., 1991a).
A number of small, clinical, non-randomised studies of
calcium intervention have shown a significant fall in rectal
mucosal proliferation in those taking calcium (Lipkin and
Newmark, 1985; Rozen et al., 1989). There have been some
small randomised placebo-controlled trials. A study by Stern
et al. (1990) was limited to 36 patients with familial polyposis
coli who had previously undergone sub total colctomy and
ileonetal anastomosis. These patients demonstrated a fall in
mucosal proliferation 3 months after the administration of
calcium, but this effect was not seen at 9 months. Wargovich
et al. (1992) reported a crossover study of 20 patients with
sporadic adenomas which was single blind and showed no
effect of calcium at a dose of 1.2gday-' but a significant
effect at 2gday-'. A further study in adenoma patients has
been reported by Bostick et al. (1993), and again no
significant effect was found.
Tbese studies have been small and lasted only a short
period of time. We have undertaken a placebo-controled,
randomised, double-blind study of calcium supplementation
in patients with adenomas. The end points were the occur-
rence of new adenomas, change in size of small adenomas
(<5 mm) left in situ and changes in mucosal proliferation.
The study is designed to run over 2 years, but we are able to
report the effects on rectal mucosal proliferation at 1
year.
P and
Patient recrsutment
Patients were recruited from a number of sources, but mainly
from the out-patient clinic and a colonoscopy clinic. After
the diagnosis of an adenoma had been made, patients were
invited by letter to take part in the study. In some, this was
prior to colonoscopy, and in others after colonoscopy.
Suitable patients were those with adenomas who were under
the age of 70, without serious medical conditions, not taking
multiple medication and who had undergone complete colon-
oscopy with ease. There were a number ofspecific exclusions,
including calcium supplement use, vegetarian diet, intake of
vitamin D or vitamin A greater than 400 IU or 10,000 IU
respectively, regular use of calcium-based antacid, renal
insuffcncY and kidney stones, renal colic in the past 20years, hyperparathyroidism, abnormal serum calcium or
serum creatinine levels at the first visit, familial polyposis,
inflammatory bowel disease or intestinal malabsorption syn-
dromes. The patients were seen by a doctor and/or study
nurse prior to recruitment to assess suitability. A total of 641
individuals were considered, and 414 were sent invitations. A
total of 138 patients responded to the invitation, ofwhom 59
(43%) declined inclusion in the study and 79 were recruited.
The patients were seen in a special dietary intervention study
clinic, the study was fully explained by a doctor (NCA and
PSR) and written consent was obtained. Blood was taken to
assess liver function tests, serum calcium and renal function.
These tests were repeated after 3 months. Recruited patients
underwent rectal biopsy 8 cm from the anal verge at 0, 3 and
12 months using no bowel preparation or after preparation
with polyethyklne glycol and electrolytes (Klean Prep, Nor-
gine, Oxford, UK), which we and others have shown to have
no effect on rectal mucosal proliferation and histological
appearance (Pockros and Foroozan, 1985; Fireman et al.,
1989; Rooney et al., 1993b). A number of samples (usually
four or five) were taken, with one being sent for histological
confirmation of normality.
Patients were randomised to receive six tablets daily, giving
a total of 1,500mg of calcium (approximately 3,000mg of
calcium carbonate) or placebo in tablet form. The tablets
looked and tasted kientical. The subjects and nmeical person-
nel involved in the trial were unaware of the treatment each
individual was taking. At each follow-up vit, questionnaires
compliance and any side-effects, inluding symptoms
and signs of hypercacaemia, abdominal pain and constipa-
tion, etc.
Mucosal proliferation was measured by the metaphase
arrest technique and the crypt cell production rate (CCPR)
alculated (Wright and Appleton, 1980, Rooney et al.,
1993b). The biopsies were dividled into 2 mm portions (exp-
lants) and placed in tissue culture mum RPMI-1640
(Gibco, Paisley, UK), to which was added 0.001% gen-
amicin (Nicholas Pharmaceuical, Slough, UK) and 10%
fetal calf serum (Sigma, Poole, UK). The samples were stored
overnight (16h) to allow for any extraction artefact (App-
leton et al., 1991b). In order to complete the assay the
explants were incubated with medium containing 1 ml of
5 sag-' ml vncristine in an atmosphere of 5% carbon dioxide
and 95% oxygen. The explants were then removed at 25, 50
and 75min, fixed in Carnoy's solution for 2-4h and then
stored in 70% ethanol (Rooney et al., 1993a,b). The tissue
was acid hydrolysed and rehydrated as described by Baroum
et al. (1992) and stained with Schifs reagent and fixed in
Carnoy's solution. The number of etaphase arrests was
counted in between 20 and 30 crypts. The crypt cell produc-
tion rate was calulated from the least-squares regreson
analysis of the data points and expd in crypt cells per
crypt per hour (ccc-'h-').
The CCPR values were compared between calcium and
placebo groups at the specified time points by Student's t-test
and within the same groups by a paired t-test. Although the
result of intervention on polyp growth and new occurrence
will need to wait until all patients have complted 2 years, we
can report the effect on CCPR at 1 year. This has been
achieved by one individual, unconnected with the study,
devising a code to allow calcium and placebo patients to be
analysed without revealing their identities.
Rests
Seventy-nine patients were randomised, 40 to calcium and 39
to placebo. There were 49 men and 39 women with a median
age of 61 years (range 34-70). As the code has not been
broken, apart from CCPR we do not yet know the make-up
of the groups with regard to risk factors. Of those patients
on medication, three were taking non-steroidal anti-inflam-
matory agents, two were on steroids and four were on H2
antagonists. The retention rate of the study has been very
high, with 75 (95%) patients raining in the tudy to 1
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year. Four patients did not complete 1 year, one died of
unrelated causes (myocardial infarction), two failed to com-
ply and the fourth developed hypercakaemic symptoms. Of
the patients remaining, the compliance was >80% based on
tablet counts and interviws by the study nurse.
The pretreatment CCPR for both groups is shown in
Figure 1. There was no staisticaBlly significant difference in
the CCPR values between the groups. The mean CCPRs
after 3 and 12 months' suppklmentation are shown in Figures
2 and 3. No signint differences in proliferation between
the calcium group and control group were observed at 3 or
12 months.
There were changes in CCPR over the time peniod. In the
calcium-treated group there was a reduction in CCPR at 3
months with a reduction in mean CCPR (SD) from 12.2
(± 5.5) ccc-'h-' before treatment to 9 (± 2.8) ccc-' h-' at
3 months (t= 3.15, d.f. = 76, P = 0.002). At 12 months this
reduction was maintained: mean CCPR 9.3 (± 3.3) ccc-' h-'
(t=2.7, d.f.=74, P=0.009). A small reduction in mean
CCPR was seen in the placebo-treated group from 10.6
(± 5.2) ccc-' h-' before treatment to 9.4 (± 2.9) ccc-' h-'
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at 3 months and 8.9 (3.3) ccc-'h'- at 12 months, but
neither reduction was statistically significnt. The changes in
CCPR between pretreatment values and those at 12 months
are shown in Figure 4.
In this randomised, double-blind, placebo-controlled trial
there was no difference in CCPR between the calcium- and
placebo-treated groups at any time point despite a fairly
large sample size and long follow-up. A number of factors
may account for this. Although not significantly different, the
mean pretreatment CCPR of the control group was lower
than that of the calium group, and this may have had an
influence. Only a proportion of individuals with adenomas
have rectal mucosal hyperproliferation, which will tend to
dilute any influence of an active agent in the whole
group.
Several studies have shown that calcium will reduce
eklvated proliferation to a 'normal' level (Lipkin and New-
mark, 1985; Lipkin et al., 1989; Rozen et al., 1989); whethr
it will reduce a 'normal' level still further is undetermined
(Lipkin et al., 1989). From our data, a reduction to 'normal'
levels was seen in both groups such that there was no differ-
ence between the two groups at 3 and 12 months. In this
study initial levels ofrectal mucosal proliferation were similar
to a previous study (Rooney et al., 1993a); after 12 months
the proliferation fell to a lower kvel of 9 ccc-l h-', a level
more consistent with our previous control group (Rooney et
al., 1993a). If there is indeed a difference between the
treatments, then larger numbers will be required in each
group to show an effect. A fall in proliferation may not be
unexpected in that Risio et al. (1991) noted a fall in prolifera-
tion 1 year after polypectomy alone. It is postlated that
dietary changes may account for this, but removal of the
neoplasm itself may have an effect. However, one would
anticipate that both groups would be affected and that ran-
domisation should have balanced this. A further factor is
that individuals in the study group may have suspected that
they were not taking calcium and actively increased their
intake of the element. Thus, there may have been an effect
within the placebo group owing to an icreased calcium
intake. Further elucidation of this point will be made once
faecal samples from the participants in the study are analysed
for calcium at the end of the study.
The rate ofrecruitment to the study was rather lower than
initially expected. In Notfingham a large number of patients
with adenomas are treated by the [epartment of Surgery,
partly because of general practitioners' referral patterns and
partly because of the faecal occult blood screening study
(Hardcastle et al., 1989). It can be seen that over 600 individ-
uals were initally considered, ofwhom over 200 wee exud-
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ed because they were over the age limit, had current medical
illness, were on other medication or were difficult to colono-
scope.
Of patients who were eligible, only about 60% of those
who responded to the initial invitation were eventually re-
cruited into the study. However, having started the study, the
rate of retention at 12 months was 95%. The high rate of
retention in the study is due to a number of factors. Firstly,
the patients were counselled carefully before being recruited
and were therefore well aware of the need to take their
tablets consistently and that the study would run for 2 years.
The second important factor was communication and rein-
forcement by our research nurse (KAG), who kept in close
contact with the subjects over the 2 year period and delivered
the medication on a 3 monthly basis, either personally or by
post. In addition a direct lie to our research secretary
ensured that the patients could easily contact the team for
advice. In mounfing further studies consideration should be
given to initial colling and continuing support for
patients recruited. It is something of a burden to continue to
take tablets over a prolonged period oftime, and a high level
ofencouragement must be given for patients to remain in the
study.
Only one patient dropped out at 12 months because of
perceived side-ects, and it is not yet known whether she
was taking calcium or placebo medication. If the calcium
group only is compared at the time points, then a reduction
in CCPR was observed, which may represent an effect. How-
ever, as previously mentioned, other randomised studies of
calcium have shown either only transient or no effect on
proliferation at this dosage (Stem et al., 1990; Wargovich et
al., 1992; Bostick et al., 1993).
The dose of calcium used was 1,500 mg daily. Initial work
by Upkin and Newmark (1985) in patients with hereditary
non-polyposis colorectal cancer utilised 1,250mg of calcium
which brought about a reduction in rectal mucosal prolifera-
tion as was found in other studies (Lipkin et al., 1989; Rozen
et al., 1989). However, Wargovich et al. (1992) recently
showed that, in their trial of patients with sporadic
adenomas, 1.2mg of calcium carbonate was insuffiient to
reduce mucosal proliferation, whereas 2.0 g did significantly
reduce rectal mucosal proliferation. The dosage that we are
using is similar to that used by the European Cooperative
Cancer Prevention (ECP) trial, which has three arms, the
others being igula husk and placebo (Faivre et al., 1991).
Our patients have been recruited and followed in a similar
way to this study and may be analysed along with them
when it matures.
We are aware of only one study which has shown an
increase in epithelial cell prolferation following calcium
supplkmentation in patients with adenomatous polyps. In this
study from The Netherlands 1.5 g ofcalcium was administer-
ed to 17 patients and, interestingly, samples were takenfrom
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the sigmoid colon (Kleibeuker et al., 1993). These workers
found that the proliferation as measured by Bromeodeoxy-
uridine labelling index increased after 12 weeks, and that in
seven patients who continued to take the medication for a
year an increase in labelling index was maintained. It is not
quite clear why the results from this study differ from other
published work. The authors suggest that calcium carbonate
is a constipating agent, leading to a prolongation of colonic
transit time, and this may expose the mucosa to faecal con-
tents for different times in the left colon as opposed to the
rectum. Overall, patients in this study have not complained
of a changing bowel habit. It is possible that there is
heterogeneity of response to calcium both in individuals and
in different parts of the colon. Our own and others' experi-
ence indicates that mucosal proliferation is similar through-
out the colon (Terpstra et al., 1987; Ponz de Leon et al.,
1988; Rooney et al., 1993b) although some other authors
have suggested that there may be a proliferation gradient
from right to left colon (Hall et al., 1992). Clearly this is an
observation which requires further study, and as our patients
come to the end of their second year in the study it should be
possible to take simultaneous left colonic and rectal biopsies
to determine whether there are any differences between
these.
In siummary, epidemiological and experimental evidence
has suggested that calcium may have a role in decreasing the
risk from colorectal cancer. We found a reduction in rectal
mucosal proliferation compared with pretreatment levels in a
group ofpatients with increased risk given calcium. However,
there was no difference overall between calcium and placebo
groups. The effect of intervention on adenomas and pro-
liferation at the end of the study is awaited.
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